Skip to navigation Skip to content


The Georgia Chapter works to improve the quality of life for people affected by MS in the state of Georgia and raise funds for critical MS research. Join the movement toward a world free of MS.


Major Advancements Made Toward Treating MS

February 19, 2014

Major Advancements Made Toward Treating

and Understanding MS Reports the National MS Society


Atlanta, GA, February 19, 2014 …The National MS Society continues to pursue all promising paths to uncover solutions for everyone with MS, wherever those opportunities exist, with particular focus on progressive MS, nervous system repair, and wellness/lifestyle. Last year, 2013, has shown positive results from previous investments in research and the Society is committed to expanding its research funding to further speed these advances.


The significant research progress that has occurred offers new leads that are driving efforts to stop MS in its tracks, restore function, and end MS forever providing better understanding on what’s causing MS damage and progression, the benefits of early and continuous treatment, and the factors that influence the body’s brain repair mechanisms.


To date, Georgia has received 5.8 million dollars toward MS research projects, including $359,000 awarded to Georgia Health Sciences University, in Augusta, to evaluate ways to measure and improve the driving ability of people with MS.  Emory University in Atlanta prepares to study how specific immune T cells drive progression of MS symptoms by studying an MS model with a $169,946 investment.


Here is a brief summary of the significant research progress made, including links to details.  Go here for a complete list of recent research progress and news.



  • The oral therapy Tecfidera was approved for relapsing MS by FDA, and positive results of peginterferon beta-1a in relapsing MS led to an application to FDA for its marketing approval. Additional studies related to emerging therapies and other topics were presented at the annual meeting of the American Academy of Neurology.


  • Progressive MS:
    • The Society joined with NIH to launch a therapy trial of the re-purposed therapy ibudilast in primary-progressive and secondary-progressive MS.
    • The global Progressive MS Alliance held its first scientific meeting to identify challenges and opportunities, and released its first request for research applications to address gaps in knowledge and research tools.


  • Lifestyle/Wellness:
    • A study suggested that smoking increases a person’s immunity to interferon, which could reduce the treatment’s benefits.
    • Dietary salt may stimulate immune activity in MS, according to studies supported by the National MS Society and others. The Society is investing in additional research to follow up this lead.
  • Researchers found a possible “biomarker” or indicator that may help predict MS disease progression. It is called Tob1, a molecule associated with immune cells, and if confirmed, it may ultimately be used to identify people who are likely to progress to full-blown MS after an initial attack.


  • There is an increased understanding that malfunctioning mitochondria, the tiny energy producers of cells (like battery packs), may contribute to nervous system damage in MS, opening up possibilities for preventing that damage. This and other reports related to understanding MS damage and its potential repair were reported at the ECTRIMS conference.


  • A report was published from the International Pediatric MS Study Group's Therapeutic Summit Workshop, outlining optimal trial designs for studying disease-modifying therapies in children with MS to improve care.


  • A large meeting of the National MS Society-launched MS Outcome Assessments Consortium and the U.S. Food and Drug Administration cleared a pathway for a new tool for improving and speeding clinical trials in MS.


Among new efforts and collaborations to drive efforts to stop MS in 2013, the Society:

  • Partnered with the Alzheimer’s Drug Discovery Foundation and the Beyond Batten’s Disease Foundation to form a collaborative research network of 10 leading universities aimed at screening drugs that show potential for treating brain diseases;


  • Provided co-funding to the UK MS Society for an innovative clinical trial testing nerve-protecting therapies in secondary-progressive MS;


  • Renewed funding for an international feasibility study (“SUMMIT”) aimed at identifying risk factors that drive MS progression.




This year witnessed growing evidence that exercise and rehabilitation can restore physical and mental functions and help people with MS live fuller lives. Progress is also accelerating in the field of nervous system repair, thanks in part to significant previous investments made by the National MS Society in an international targeted initiative. Repairing the myelin insulation on the wire-like axons is thought to be important not only for restoring nerve signaling and function, but also for shielding axons from further harm. View a recording of a recent Webcast related to nervous system repair and protection.



  • Nervous System Repair:
  • The first Phase 2 trial was launched of “anti-LINGO” investigational therapy aimed at stimulating myelin repair in people with MS.
  • Two mouse studies in the U.S. and Italy showed potential of stem cells derived from the skin for growing new myelin and for reducing nervous system damage.
  • The first Barancik Prize winner innovated technology to  screen on–the-shelf drugs for myelin repair potential; a clinical trial is now starting based on a  therapy uncovered by this system.
  • Studies from three labs provided basic clues to nervous system damage and factors controlling repair of the brain’s insulating myelin, which if confirmed could eventually be translated to promising new therapeutic approaches to stimulating myelin repair to restore function in people with MS.
  • Society-supported researchers used non-invasive imaging called PET (positron emission tomography) to visualize the loss and repair of myelin in rats over time, which can be used to identify compounds with future potential to treat MS.


  • Another step toward improving MS symptoms was taken when Canbex Therapeutics, the recipient of early funding from the Society through Fast Forward, leveraged new funding to launch a clinical trial of an oral investigational therapy to treat debilitating muscle spasms (spasticity) experienced by many with MS.


  • Lifestyle/Wellness:
    • A small study suggested that aerobic exercise has potential for broad benefits for people with MS including improving memory and building brain circuitry.
    • A clinical trial showed strong evidence that a specific type of memory training improves learning in people with MS and benefits other aspects of quality of life.
    • Additional studies on exercise and rehabilitation in MS were presented at the ECTRIMS conference


To drive additional progress toward restoring what’s been lost in MS, in 2013 the Society also:

  • Initiated funding for a clinical trial to determine whether aerobic exercise can improve cognitive impairment in people with MS;


  • Partnered with the University of Miami and Accera, Inc. to test novel “Medical Food” for MS cognitive impairment;


  • Invested in commercial therapy development programs through Fast Forward, focusing on novel therapies to protect the nervous system from MS damage and/or stimulate myelin repair. These include CuroNZ’s NRP2945, ENDECE Neural’s NDC-1308, Karo Bio AB’s ERbeta agonists, and Karyopharm Therapeutics Inc.’s Selective Inhibitors of Nuclear Export (SINE) compounds.



Progress was made identifying some factors that may combine to increase a person’s chances of developing MS, such as specific genes, infections, and lifestyle factors. None of these factors is a single cause of the disease, and it’s clear that not everyone who has MS has been exposed to these factors, nor that everyone who is exposed to these factors will develop MS. These clues provide insights that may ultimately lead to ways to prevent the disease:


  • A global consortium identified 48 new MS risk genes, with funding from the National MS Society and others, which better define the biological pathways leading to MS and may ultimately lead to ways to prevent the disease and enhance the design of better treatments.




To further efforts to end MS forever, in 2013 the Society:

  • Recruited experts to launch the MS Prevalence Work Group, and engaged a consulting group, to begin work that will provide an updated estimate of MS prevalence in the US;


  • Launched new research funding totaling $2.5 million for an expanded Network of Pediatric MS Centers and data coordination hub, which can be leveraged to answer important research questions to advance our understanding of the disease in both children and adults with MS.


This has been a year of significant research progress, bringing us closer to solutions for everyone with MS. Looking ahead, the Society is committed to fueling research by increasing its annual investment to $50 million in 2014 – because understanding and ending MS can’t come fast enough.


About Multiple Sclerosis 

Multiple sclerosis, an unpredictable, often disabling disease of the central nervous system, interrupts the flow of information within the brain, and between the brain and body.



About the National Multiple Sclerosis Society and Fast Forward, LLC

The Society mobilizes people and resources to drive research for a cure and to address the challenges of everyone affected by MS.  To fulfill this mission, the Society funds cutting-edge research, drives change through advocacy, facilitates professional education, collaborates with MS organizations around the world, and provides programs and services designed to help people with MS and their families move their lives forward.  In 2013 alone, through its home office and 50-state network of chapters, the Society invested $48.3 million to support 380 new and ongoing research projects around the world. The Society is dedicated to achieving a world free of MS. Join the movement at


Fast Forward, LLC was established by the National Multiple Sclerosis Society as part of a comprehensive approach to MS research and treatment, focusing on accelerating commercial development of promising research discoveries.  Through Fast Forward, the Society connects university-based MS research with private-sector drug development and funds small biotechnology/pharmaceutical companies to develop innovative new MS therapies and repurpose FDA-approved drugs as new treatments for MS. For more information, please visit or more information, please visit




About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.


Chapter Home News
Master Page Does Not Exist